A new trading day began on Friday, with Akero Therapeutics Inc (NASDAQ: AKRO) stock price up 4.87% from the previous day of trading, before settling in for the closing price of $30.83. AKRO’s price has ranged from $11.92 to $37.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -24.87%. With a float of $58.10 million, this company’s outstanding shares have now reached $69.43 million.
The extent of productivity of a business whose workforce counts for 56 workers is very important to gauge. In terms of profitability, gross margin is 96.83%, operating margin of -82458.8%, and the pretax margin is -71892.96%.
Akero Therapeutics Inc (AKRO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 16.31%, while institutional ownership is 98.24%. The most recent insider transaction that took place on Nov 01 ’24, was worth 505,105. In this transaction Chief Development Officer of this company sold 15,485 shares at a rate of $32.62, taking the stock ownership to the 74,158 shares. Before that another transaction happened on Oct 30 ’24, when Company’s Chief Development Officer sold 4,515 for $32.53, making the entire transaction worth $146,855. This insider now owns 74,158 shares in total.
Akero Therapeutics Inc (AKRO) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.71 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.87% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Here are Akero Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 24.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.41, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -3.90 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
The latest stats from [Akero Therapeutics Inc, AKRO] show that its last 5-days average volume of 0.67 million was inferior to 0.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 65.58%. Additionally, its Average True Range was 1.48.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 94.80%, which indicates a significant increase from 86.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.20% in the past 14 days, which was lower than the 47.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.33, while its 200-day Moving Average is $24.60. Now, the first resistance to watch is $33.22. This is followed by the second major resistance level at $34.11. The third major resistance level sits at $35.27. If the price goes on to break the first support level at $31.17, it is likely to go to the next support level at $30.01. Assuming the price breaks the second support level, the third support level stands at $29.12.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
With a market capitalization of 2.35 billion, the company has a total of 69,431K Shares Outstanding. Currently, annual sales are 0 K while annual income is -151,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -55,990 K.
